AR and prostate cancer: The androgen receptor inhibitor enzalutamide has demonstrated consistent benefits in men with prostate cancer at various stages of the disease, from hormone-sensitive prostate cancer (HSPC) to metastatic (m) and non-metastatic (nm) castration-resistant prostate cancer (CRPC) [1,2,3,4,5].